Skip to Content
Biotechnology and health

CRISPR for high cholesterol: 10 Breakthrough Technologies 2023

New forms of the gene-editing tool could enable treatments for common diseases.

""
Amrita Marino

WHO

Verve Therapeutics, Beam Therapeutics, Prime Medicine, Broad Institute

WHEN

10 to 15 years

Last year, a New Zealand woman became the first to receive a gene-editing treatment to permanently lower her cholesterol. The woman had heart disease, along with an inherited risk for high cholesterol. But scientists behind the experimental treatment think it could help pretty much anyone.  

The trial is a potential turning point for CRISPR, the editing tool they used. Since the technology was first programmed to edit genomes about a decade ago, we’ve seen CRISPR move from scientific labs to clinics. But the first experimental treatments have focused on rare genetic disorders. A high-cholesterol treatment has wider potential. 

The cholesterol-lowering treatment, developed by Verve Therapeutics, relies on a form of gene editing called base editing, or “CRISPR 2.0.” It’s a more targeted approach—instead of simply making cuts to shut off specific genes, scientists can now swap a single DNA base for another. In theory, this should be safer because you’re less likely to cut an important gene by mistake, and you can avoid potential errors that may occur when DNA repairs itself after being cut. 

An even newer form of CRISPR could take things further still. Prime editing—or “CRISPR 3.0”—allows scientists to insert chunks of DNA into a genome. If it works in people, it could let scientists replace disease-causing genes.  

Together, these newer forms of CRISPR could broaden the scope of gene editing to take on many conditions—not all of them genetic. Someday, people may have the option to add genes thought to protect against high blood pressure, or certain diseases, to their genetic code.   

All CRISPR treatments are experimental at this point, and we don’t know if they’re safe. Some argue we should focus on treating those with severe diseases in the meantime. But if these new forms of CRISPR do work, they could help many others.

Read more about how CRISPR might be ready to go mainstream.

Deep Dive

Biotechnology and health

The Biggest Questions: What is death?

New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.

I received the new gene-editing drug for sickle-cell disease. It changed my life.

As a patient enrolled in a clinical trial for Vertex’s new treatment, I was among the first to experience CRISPR’s transformative effects.

The lucky break behind the first CRISPR treatment

Gene editing for sickle-cell is here. This is how researchers knew what DNA to change.

Medical microrobots that can travel inside your body are (still) on their way

Microrobots released into the body could bust up clots, deliver cancer drugs, and even guide listless sperm to their target.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.